Hence, once we proposed the 34 essential inflammatory response proteins strongly linked to physiological phenotypes of COVID-19, we used the COVID-19 Target Prioritization Tool from the Open Target Platform (Carvalho-Silva et al., 2019) to identify 3 small molecules (baricitinib, eritoran, and montelukast) involved in phases III/IV clinical trials that acts on 3 therapeutic targets (JAK2, TLR4, and CYSLTR1). Here, JAK2 is linked to COVID-19.